DCM
SRNE

Dupont Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Dupont Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-39,757
Closed -$346K – 714
2015
Q4 		$346K Buy
39,757
+19,728
+98% +$166K 0.01% 601
2015
Q3 		$168K Buy
+20,029
New +$319K ﹤0.01% 580

Other funds holding SRNE

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dupont Capital Management's SRNE Position: Q1 2016 in Review

Dupont Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2016, closing a stake of 39,757 shares — an estimated $346K sold.

Dupont Capital Management first reported a position in SRNE in Q3 2015 and held it in 2 quarters. The position peaked at $346K in Q4 2015. 68 funds tracked by Wall St. Rank hold SRNE as of Q1 2016.

  • Dupont Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Dupont Capital Management sold 39,757 Sorrento Therapeutics, Inc. shares in Q1 2016, an estimated $346K.
  • Dupont Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q3 2015 and held it in 2 quarters.
  • Dupont Capital Management's Sorrento Therapeutics, Inc. position peaked at $346K in Q4 2015.
  • 68 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2016.

Based on Dupont Capital Management's 13F filing for Q1 2016, filed 28 Apr 2016.